In this article MU LLY NFLX LCID DLTR ASML-NL Check out the companies making headlines before the bell: Micron Technology (MU) – Micron reported adjusted quarterly earnings of $2.42 per share, 9 cents above estimates, with the chip maker’s revenue also topping Street forecasts. However, its current-quarter forecast fell below consensus, due to computer-making customers
0 Comments
Europeans are leaving their houses to go shopping, eat out, travel and visit cinemas as much as they did before the pandemic, in a sign of returning consumer confidence which suggests that the eurozone’s economic rebound remains intact, for now. Despite a slew of worrying economic news — from high energy bills that threaten household
0 Comments
A recent New York case underscored just how easily an exchange of email messages can create a binding contract. Though the dispute involved a litigation settlement evidenced in an exchange of emails, the same principles would apply in real estate contracts or any other area of commerce that involves written agreements. New York’s procedural rules
0 Comments
Verifone, a global payment system provider with 35 million devices in 150 countries, is rolling out crypto payment support in the U.S. in partnership with Bitpay. Verifone’s platform processes more than $440 billion annually. The company says, “the appetite for crypto payments has exploded this year.” Major Retailers Will Soon Be Able to Accept Cryptocurrency
0 Comments
State and local governments would be encouraged to consider public-private partnerships for complicated projects like rural broadband or large transportation developments under the bipartisan infrastructure bill being debated by Congress this week. The legislation doubles private activity bond volume for surface transportation projects to $30 billion from $15 billion, a central financing tool for P3
0 Comments
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher. IShares Nasdaq Biotechnology ETF: https://www.zacks.com/funds/etf/IBB/profile?cid=CS-YOUTUBE-FT-VID SPDR S&P Biotech ETF: https://www.zacks.com/funds/etf/XBI/profile?cid=CS-YOUTUBE-FT-VID ARK Genomic Revolution ETF: https://www.zacks.com/funds/etf/ARKG/profile?cid=CS-YOUTUBE-FT-VID Virtus LifeSci Biotech Clinical Trials ETF: https://www.zacks.com/funds/etf/BBC/profile?cid=CS-YOUTUBE-FT-VID ALPS Medical Breakthroughs ETF: https://www.zacks.com/funds/etf/SBIO/profile?cid=CS-YOUTUBE-FT-VID Merck: https://www.zacks.com/stock/quote/MRK?cid=CS-YOUTUBE-FT-VID Biogen: https://www.zacks.com/stock/quote/BIIB?cid=CS-YOUTUBE-FT-VID Sanofi: https://www.zacks.com/stock/quote/SNY?cid=CS-YOUTUBE-FT-VID ArQule: https://www.zacks.com/stock/quote/ARQL?cid=CS-YOUTUBE-FT-VID Synthorx: https://www.zacks.com/stock/quote/THOR?cid=CS-YOUTUBE-FT-VID Follow us on StockTwits: http://stocktwits.com/ZacksResearch Follow
0 Comments
Traditionally, Northern Manhattan and the Bronx have been led by the multifamily asset class.  The market for development site sales also primarily focuses on this asset class, with affordable and rent-stabilized housing leading the market. While the Bronx has lately seen a huge resurgence of interest in industrial properties and Northern Manhattan has a growing
0 Comments